Naprosyn, Anaprox, Anaprox DS Articles
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
Shionogi set to buy Victory for $150M
19 May 2009
Pozen to get milestone as AZ files for PN 400
15 May 2009
Naproxcinod does not increase blood pressure
2 April 2009
Victory Pharma closes $45M equity financing
16 March 2009
Watson and Elan in naproxen settlement
16 March 2009
NicOx "on the brink" of becoming a drugmaker
9 March 2009
Naproxcinod reduces blood pressure in OA
12 January 2009
Naproxcinod reduces systolic and diastolic blood pressure in pooled Ph III analysis
22 December 2008
UK warning on Internet Rx drugs
15 December 2008
NicOx shares up 44% on strong late-stage data
10 November 2008
Pozen shares drop 28% on Treximet challenge
27 October 2008
Design of Pozen studies under scrutiny by FDA
27 October 2008
Court rules against Watson on Naprelan patent
18 August 2008
NicOx complete enrollment in Ph III OA trial
28 July 2008
Strong blood pressure profile for NicOx' naproxcinod
23 June 2008
NicOx swings to a loss in 1st-qtr p R&D costs
26 May 2008
$20M GSK milestone for Pozen
5 May 2008
Maryland OKs Medicaid reimbursement for ActiPatch
28 April 2008
GSK's Treximet receives FDA approval
21 April 2008
UK Pom to P switch for Bayer's naproxen
7 April 2008
NicOx initiates two ABPM naproxcinod trials
10 March 2008
PDCO recommends PIPs for four drugs
3 March 2008
UPDATE: EMEA to withdraw lumiracoxib approval
24 December 2007
NicOx enrolls Ph III naproxcinod trial
24 December 2007
Naproxcinod superior to naproxen in Ph III OA trial
19 November 2007
Strong ABPM data for naproxcinod vs naproxen
12 November 2007
NSAIDs linked to risk of urinary retention
17 September 2007
Australia's TGA withdraws Novartis' coxib OA painkiller Prexige on liver safety fears
20 August 2007
Trexima receives second approvable letter
13 August 2007
Logical Thera raises $30M to advance R&D
18 June 2007
UK's MHRA consults on P status naproxen
30 April 2007
Pozen submits full Trexima response to FDA
20 November 2006
Positive Ph III for NicOx' naproxcinod
6 November 2006
NicOx reports encouraging top-line Ph III data for naproxcinod
6 November 2006
Pozen gets $40M upfront payment from AstraZeneca
2 October 2006
Early Trexima use cuts migraine symptoms
2 October 2006
Pozen signs PI+NSAID deal with AstraZeneca
11 September 2006
AstraZeneca and Pozen to co-develop pain drug
7 August 2006
Migraine combo-therapy evaluated
3 July 2006
FDA delays decision on Pozen/GSK's Trexima
19 June 2006
NicOx starts enrolling in trial of HCT 3012
8 May 2006
Study links Pfizer's painkiller Celebrex to an increased risk of myocardial infarction
13 March 2006
Dr Reddy's of India sees revenues grow 25% and earnings rocket in fiscal third quarter
6 February 2006
Pozen's MT 100 approved in UK
5 December 2005
FDA sets date for review of Pozen's drug
11 July 2005
POZEN/GSK's Trexima on target for NDA
27 April 2005
Naproxen is safe and effective when taken as directed
14 March 2005
Bayer says FDA committee supports Aleve safety
28 February 2005
US FDA panel says COX-2s can be sold, OKs Vioxx' return to market?
28 February 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
Novartis considers limited initial approval of Prexige in the USA
14 February 2005
Bayer submits naproxen safety profile to FDA
14 February 2005
Euro patent for Pozen's migraine drug
31 January 2005
Stock Commentary - Europe
10 January 2005
NIH: no higher CV risk seen in ADAPT study with Celebrex
10 January 2005
Bayer and Stada hit by FDA warning on naproxen
10 January 2005
Recordati obtains new drug in Spain
5 July 2004
Promising Ph II results for NicOx' HCT 3012
21 June 2004
Pozen's MT 100 "not approvable"
7 June 2004
Pozen/GSK's Trexima enters Phase III
24 May 2004
US FDA to educate about OTC painkillers
2 February 2004
FDA rejects Pozen's lead migraine product
27 October 2003
Pozen files NDA in the USA for MT 100
11 August 2003
Celebrex GI safety study
26 May 2003
NicOx "clarifies" data position on AZD3582
17 March 2003
USA's FTC probing Elan, Skye and AstraZeneca
10 March 2003
NicOx requests enquiry following share collapse
3 March 2003
First launch, in Canada, for AstraZeneca's superstatin Crestor
24 February 2003
AstraZeneca/NicOx' painkiller: mixed data
24 February 2003
US consumers
10 February 2003
Pozen gets OK for rapid migraine drug dev't
12 August 2002
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
